Mechelen, Belgium; 26 June 2007 - Galapagos NV (Euronext & LSE: GLPG) announced today that Wyeth (NYSE:WYE - News) has exercised its right to license three proprietary bone anabolic drug targets from their 2003 research agreement in osteoporosis, resulting in a EUR 1.05 million milestone payment to Galapagos.
